Journal
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
Volume 64, Issue 2, Pages 266-271Publisher
WILEY
DOI: 10.1111/dmcn.15025
Keywords
-
Categories
Funding
- Children's Hospital at Westmead
- NHMRC
- Petre Foundation
- Cerebral Palsy Alliance
Ask authors/readers for more resources
In the treatment of Aicardi-Goutières syndrome (AGS), Janus kinase (JAK) 1 inhibition shows a precision medicine approach targeting type I interferon-mediated cell signaling. Elevated cerebrospinal fluid (CSF) neopterin levels in AGS patients decreased significantly in response to JAK inhibitors, indicating a potential role for CSF neopterin as a biomarker of treatment response.
Janus kinase (JAK) 1 inhibition represents a precision medicine approach in the treatment of Aicardi-Goutieres syndrome (AGS), through targeting of type I interferon-mediated cell signalling. Blood interferon mRNAseq has been proposed as a biomarker of disease with utility in therapeutic monitoring. Objective cerebrospinal fluid (CSF) biomarkers tracking treatment efficacy are currently lacking. Here, we report a retrospective case series of 13 patients (median age 6y, range 2y 6mo-17y; five females, eight males) with AGS demonstrating significantly elevated CSF neopterin levels at first sampling (median 200nmol/L, range 45-2024nmol/L), compared to 13 age-matched controls with non-inflammatory neurological conditions (median 23nmol/L, range 5-34nmol/L, p<0.001). Five patients with AGS treated with JAK inhibitors demonstrated a median 81.5% reduction of CSF neopterin (range -36% to -88% change from baseline), compared to eight untreated patients with AGS demonstrating a median 7% reduction in CSF neopterin (range -63% to +117% change) (p=0.047). Our data indicate a biological effect of JAK inhibitors, and the potential role of CSF neopterin as a biomarker of treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available